BioNTech Investor Day Presentation Deck
BNT211
An ORR 43% and DCR of 86% (6 PR, 5 SD+, 1 SD) were achieved at 6 weeks
Mono
DL1
Combo
DL1
Mono
DL2
Pat#1
Pat#2
Pat#3
Pat#1
Pat#2
Pat#3
Pat#1
Pat#2
Pat#3
Pat#4
Pat#5
Pat#6
Pat#1
Pat#2
Combo Pat#3
DL2 Pat#4
Pat#5
Pat#6
Pat#1
(50% lymphodepletion)
ACT
CR
PR
SD +
SD
PD
Redosing
Mono Combo
* EOT
Testicular
Cell therapies
Ovarian
Others
Non-evaluable
Not included
6 weeks
12 weeks 18 weeks 24 weeks 30 weeks 36 weeks 42 weeks 48 weeks
In testicular cancer at DL2 (n=5, incl. reduced LD): Best overall response rate-80%, DCR 100% (1 CR, 3 PR, 1 SD+)
Data cut-off: March 10, 2022; first assessment, 6 weeks post infusion.
ACT, adoptive cell transfer; CR, complete response; DCR, disease control rate; EoT, end of trial (due to PD); PD, progressive disease; PR, partial response; SD (+), stable disease (with shrinkage of target lesions).
Haanen J, et al. AACR Annual Meeting 2022; Oral presentation CT002.
BIONTECH
136View entire presentation